FACTORS ASSOCIATED WITH CONTINUATION OF PALIPERIDONE PALMITATE 1-MONTH FORMULATION MONOTHERAPY IN PATIENTS WITH SCHIZOPHRENIA

被引：0

作者：

Marumoto, Tatsuro ^{[1
]}

Horio, Hiroshi ^{[1
]}

Kinoshita, Hiroaki ^{[2
]}

Morita, Natsuko ^{[2
]}

Touma, Tokiko ^{[3
]}

Takebe, Kyoko ^{[2
]}

Wakamatsu, Akihide ^{[1
]}

机构：

[1] Janssen Pharmaceut KK, Med Affairs Div, Tokyo, Japan

[2] Janssen Pharmaceut KK, Drug Safety Surveillance Dept, Japan Safety & Surveillance Div, Tokyo, Japan

[3] Janssen Pharmaceut KK, Stat & Decis Sci Japan, Tokyo, Japan

来源：

关键词：

paliperidone palmitate 1-month formulation; LAI monotherapy; schizophrenia; ANTIPSYCHOTIC-DRUG USE; COHORT;

D O I：

10.1093/ijnp/pyae059.277

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

pyae059.27

引用

页码：i160 / i161

页数：2